The ISCHEMIA trial enables countless sub-studies. Many of them have made part of the virtual ACC 2020, and among them you will find the present study. This analysis finds it is the anatomy — rather than ischemia — which predicts events. And even more interesting is the fact that revascularizing this particular anatomy will not<a href="https://solaci.org/en/2020/04/01/virtual-acc-2020-relationship-between-ischemia-severity-and-cad/" title="Read more" >...</a>
According to a recent study published in Circ. Cardiovasc Interv, after a scheduled angioplasty, the rate of arrhythmia requiring some kind of treatment is very low, low enough to deem unnecessary the routine monitoring of all patients. The standard policy at many institutions is continuous cardiac monitoring for several hours after undergoing coronary angioplasty, with<a href="https://solaci.org/en/2020/02/04/routine-continuous-monitoring-after-angioplasty-might-not-be-necessary/" title="Read more" >...</a>
After coronary angioplasty, the use of drugs whose efficacy for the reduction of major events has been proven declines over time, which is associated with worse patient prognosis. Sometimes, without meaning to, we convey to patients the idea that, once the stent has been implanted, the artery is “cured” or that the only potential future<a href="https://solaci.org/en/2019/12/26/secondary-prevention-a-responsibility-we-should-not-delegate/" title="Read more" >...</a>
This COMPLETE sub-study using optical coherence tomography (OCT) showed the prevalence of vulnerable lesions other than the culprit which should provide a physiopathological explanation of the benefit of complete revascularization observed in the original study. STEMI patients with multivessel disease will benefit from complete revascularization in terms of reduced cardiovascular death and repeat MI according<a href="https://solaci.org/en/2019/11/27/aha-2019-complete-complete-revascularization-is-superior-since-it-treats-other-vulnerable-plaque/" title="Read more" >...</a>
1- ESC 2019 | New European Guidelines on “Chronic Coronary Syndromes” In Paris, during the European Society of Cardiology (ESC) Congress 2019 Scientific Sessions, new guidelines for the diagnosis and treatment of chronic coronary syndromes were presented. This document, simultaneously published in Euro Heart J, updates the 2013 guidelines on stable ischemic heart disease and<a href="https://solaci.org/en/2019/10/21/the-most-read-scientific-articles-in-september-at-solaci-org/" title="Read more" >...</a>
The XXXIX Regional SOLACI Sessions in Panama were an extremely successful scientific event. Renowned specialists in hemodynamics from all over Latin America presented their works and shared their knowledge in an event characterized by the utmost respect and comradeship. That is the reason why we share below those presentations, thanking these professionals for their contribution to our<a href="https://solaci.org/en/2019/10/21/see-the-2019-panama-sessions-presentations/" title="Read more" >...</a>
Courtesy of SBHCI. The COMPLETE study was carried out to assess the benefit of complete revascularization vs culprit vessel revascularization in the context of ST elevation acute myocardial infarction. This COMPLETE sub-study presented at TCT 2019 scientific sessions simultaneously published in JACC assessed the optimal timing of complete revascularization. The general study had already shown<a href="https://solaci.org/en/2019/10/01/tct-2019-complete-sub-study-to-find-out-complete-optimal-revascularization-timing-in-stemi/" title="Read more" >...</a>
Courtesy of SBHCI. Between 16 and 18% of coronary artery lesions in patients with chronic stable CAD are chronic total occlusions (CTO). CTO revascularization could benefit symptomatic patients, but it remains unclear whether such complex procedure is safe in the long run, given the study outcomes on PCI in CAD so far. This study presented<a href="https://solaci.org/en/2019/10/01/tct-2019-euro-cto-results-at-3-years-of-cto-recanalization-vs-optimal-medical-treatment/" title="Read more" >...</a>
Myocardial revascularization surgery is still one of the most effective treatment strategies against coronary disease. One of the most important advantages of surgery over angioplasty is the chance to reach complete revascularization. This has proven to improve the survival of patients and to reduce the number of cardiovascular events. The choice of conduit for the<a href="https://solaci.org/en/2019/09/26/best-conduits-and-best-surgeons-for-the-best-outcome/" title="Read more" >...</a>
SOLACI continues their mission to foster the development of interventional cardiology in Latin America. In this regard, they will be part of a joint session together with the Mexican Interventional Cardiology Society at SOCIME 2019, to be held on October 10 thru 12 at Santa Fé Westin Hotel in Mexico City. The symposium will present<a href="https://solaci.org/en/2019/09/26/solaci-symposium-at-socime-congress-2019/" title="Read more" >...</a>